Almost ~ 100 million people in the US have type 2 diabetes (T2D) or pre-diabetes that accounts for 1 in 5 health care dollars. The prevalence of these metabolic disorders is increasing exponentially. Understanding the pathogenesis of, and developing rational therapies based on the pathogenic factors for these conditions is a very high priority. The exact mechanism of nocturnal regulation of glucose production in humans remains poorly understood. There is controversy regarding whether the higher fasting glucose concentration observed in T2D is due to inappropriate counter-regulatory hormone secretion (i.e., glucagon and cortisol) for the prevailing glucose concentrations throughout the night or during early morning hours alone resulting in insulin resistance and consequent higher glucose production;or perhaps to a disruption of the biological clock in the overnight fasted state. In th previous grant cycle we have shown that people with T2D have higher fasting and post prandial glucose concentrations as a result of abnormal regulation of glucose production and glucose uptake. The current application is designed to systematically investigate the pathophysiology of overnight regulation of glucose production in T2D in specific aim 1, the relative contributions of cortisol and glucagon to nocturnal glucose homeostasis in specific aim 2, and the extent to which these effects differ from anthropometrically matched nondiabetic subjects. Finally, in specific aim 3, we will conduct a clinical trial to determine the effect of metformin vs. insulin glargine on hepatic response to glucagon in T2D.
Specific Aim 1 will determine the rates of endogenous glucose production in T2D and nondiabetic subjects at 1, 4 and 7 AM. To minimize confounding effects of sleep, subjects with a history of sleep disorders will be excluded. Moreover, subjects will stay at clinical research unit (CRU) for 2 nights and 1 day so as to be familiarized to the CRU environment on the first night and measures in place to minimize sleep disruption during study period on the second night. Rates of gluconeogenesis will be measured using 2H2O.
Specific Aim 2 A will test the effects of nocturnal cortisol concentrations on glucose production in T2D and nondiabetic subjects. Endogenous cortisol production will be blocked by metyrapone during constant vs. rising overnight cortisol infusions in random order. Rates of endogenous glucose production will be estimated overnight and at 7 AM. We will also evaluate insulin induced suppression of endogenous glucose production in each group at constant vs. rising cortisol concentrations during matched portal insulin and glucagon concentrations with a somatostatin clamp.
Specific Aim 2 B will determine the effects of nocturnal glucagon concentrations on rates of endogenous glucose production in T2D and nondiabetic subjects. Endogenous glucagon secretion will be blocked by somatostatin during constant vs. rising overnight glucagon infusions in random order. We will test whether insulin induced suppression of endogenous glucose production is lower in T2D than nondiabetic subjects during rising glucagon concentrations. We will also determine whether glycogenolysis rates are higher in T2D in the presence of rising glucagon concentrations. To explore the extent to which metformin therapy alters the hepatic response to glucagon in people with T2D in Specific Aim 3, T2D subjects will undergo euglycemic clamp studies with glucagon doses at 0.65, 1.5 and 3.0 ng/kg/min (in the presence of somatostatin) to estimate rates of endogenous glucose production before and following randomization to either two weeks of metformin or insulin glargine therapy. A better understanding of factors that impact the nocturnal regulation of glucose metabolism will help to develop rational therapeutic approaches to manage individuals with T2D in the future.
Almost 300 million people worldwide have either type 2 diabetes or pre-diabetes. The diagnostic hallmark of these conditions is elevated blood sugar levels first thing in the morning. Therefore, this application focuses on how and why the liver releases excess glucose into the blood stream during the night and early morning in people with type 2 diabetes and whether metformin (a commonly used antidiabetic medication) can modulate some of the causal factors. Type 2 diabetes cause tremendous amount of human suffering and result in enormous costs to the economy as well as heath care systems worldwide. The ultimate goal of the studies proposed in this application is to improve our understanding of these disorders in order to develop rational approaches for their prevention, treatment and hopefully ultimate cure.
|Kudva, Yogish C; Carter, Rickey E; Cobelli, Claudio et al. (2014) Closed-loop artificial pancreas systems: physiological input to enhance next-generation devices. Diabetes Care 37:1184-90|
|Basu, Rita; Johnson, Matthew L; Kudva, Yogish C et al. (2014) Exercise, hypoglycemia, and type 1 diabetes. Diabetes Technol Ther 16:331-7|
|Dube, Simmi; Norby, Barbara; Pattan, Vishwanath et al. (2014) Hepatic 11?-hydroxysteroid dehydrogenase type 1 activity in obesity and type 2 diabetes using a novel triple tracer cortisol technique. Diabetologia 57:1446-55|
|Limberg, Jacqueline K; Taylor, Jennifer L; Dube, Simmi et al. (2014) Role of the carotid body chemoreceptors in baroreflex control of blood pressure during hypoglycaemia in humans. Exp Physiol 99:640-50|
|Cobelli, Claudio; Dalla Man, Chiara; Toffolo, Gianna et al. (2014) The oral minimal model method. Diabetes 63:1203-13|
|Dalla Man, Chiara; Piccinini, Francesca; Basu, Rita et al. (2013) Modeling hepatic insulin sensitivity during a meal: validation against the euglycemic hyperinsulinemic clamp. Am J Physiol Endocrinol Metab 304:E819-25|
|Rajpal, Aman; Dube, Simmi; Carvalho, Filipa et al. (2013) Effects of transaldolase exchange on estimates of gluconeogenesis in type 2 diabetes. Am J Physiol Endocrinol Metab 305:E465-74|
|Basu, Rita; Barosa, Cristina; Jones, John et al. (2013) Pathogenesis of prediabetes: role of the liver in isolated fasting hyperglycemia and combined fasting and postprandial hyperglycemia. J Clin Endocrinol Metab 98:E409-17|
|Basu, Ananda; Kudva, Yogish C; Basu, Rita (2013) GPR40 modulators: new kid on the block. Diabetes Care 36:185-7|
|Dube, S; Errazuriz, I; Cobelli, C et al. (2013) Assessment of insulin action on carbohydrate metabolism: physiological and non-physiological methods. Diabet Med 30:664-70|
Showing the most recent 10 out of 131 publications